pirenzepine has been researched along with Dysthymic Disorder in 1 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Dysthymic Disorder: Chronically depressed mood that occurs for most of the day more days than not for at least 2 years. The required minimum duration in children to make this diagnosis is 1 year. During periods of depressed mood, at least 2 of the following additional symptoms are present: poor appetite or overeating, insomnia or hypersomnia, low energy or fatigue, low self-esteem, poor concentration or difficulty making decisions, and feelings of hopelessness. (DSM-IV)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients suffering from BPD and dysthymia were included in an 8-week, open-label study of olanzapine monotherapy." | 9.09 | Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. ( Berry, SA; Camlin, KL; Jesberger, JA; Schulz, SC, 1999) |
| "Patients suffering from BPD and dysthymia were included in an 8-week, open-label study of olanzapine monotherapy." | 5.09 | Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. ( Berry, SA; Camlin, KL; Jesberger, JA; Schulz, SC, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schulz, SC | 1 |
| Camlin, KL | 1 |
| Berry, SA | 1 |
| Jesberger, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind and Placebo Controlled Assessment of Depakote ER in Borderline Personality Disorder[NCT00222482] | 15 participants | Interventional | 2003-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for pirenzepine and Dysthymic Disorder
| Article | Year |
|---|---|
Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Borderline Personality Disorder; Brief Psychiatric Rat | 1999 |